GBA Presents: THE GREEN MARKET
- Thread starter stonedinvestor
- Start date
Stoney!!!!
Down 20% from your bottom call.
Chewy closed at $60, 52 week low $57
$61 pre-market.
Earnings tonight....
One would think this heads up today.
It probably will, I'm a little leery though.
More to follow.
Gummy watch:
FIZZ
$52
National Beverage Corp. Again Enriches the Holiday Season With a Special Cash Dividend
National Beverage Corp. (NASDAQ: FIZZ) today announced its Board of Directors has declared a special cash dividend of $3.00 per share to shareholders of record on December 13, 2021. FIZZ will trade ex-dividend on December 10, 2021 and the payment date for this distribution will be on or before February 11, 2022.
“With this special cash dividend, our eleventh in the past 17 years, FIZZ holders will have received $13.28 per share or over $1.2 billion,” stated a company spokesperson. “Our superior performance and innovative products have continued to generate strong operating cash flow and allowed us to reward shareholders while maintaining one of the industry’s strongest balance sheets. As our nation faces new and lingering pandemic-related concerns, supply chain issues and uncertainty regarding future tax legislation, we feel exceptionally blessed to brighten this holiday season for loyal FIZZ holders.”
“One of Team National’s profound tenets is its dedication to do good and give back. Since the beginning of the pandemic, we have refreshed devoted hospital workers with shipments of LaCroix and continue our steadfast support of numerous community groups and charitable organizations. Our sincere hope is to share our mission of giving to others and bringing joy throughout this special time of year,” the spokesperson concluded.
National Beverage plans to announce results for its second quarter ended October 30, 2021 on or before December 9, 2021.
“Patriotism” – If Only We Could Bottle It!
FIZZ
$52
National Beverage Corp. Again Enriches the Holiday Season With a Special Cash Dividend
National Beverage Corp. (NASDAQ: FIZZ) today announced its Board of Directors has declared a special cash dividend of $3.00 per share to shareholders of record on December 13, 2021. FIZZ will trade ex-dividend on December 10, 2021 and the payment date for this distribution will be on or before February 11, 2022.
“With this special cash dividend, our eleventh in the past 17 years, FIZZ holders will have received $13.28 per share or over $1.2 billion,” stated a company spokesperson. “Our superior performance and innovative products have continued to generate strong operating cash flow and allowed us to reward shareholders while maintaining one of the industry’s strongest balance sheets. As our nation faces new and lingering pandemic-related concerns, supply chain issues and uncertainty regarding future tax legislation, we feel exceptionally blessed to brighten this holiday season for loyal FIZZ holders.”
“One of Team National’s profound tenets is its dedication to do good and give back. Since the beginning of the pandemic, we have refreshed devoted hospital workers with shipments of LaCroix and continue our steadfast support of numerous community groups and charitable organizations. Our sincere hope is to share our mission of giving to others and bringing joy throughout this special time of year,” the spokesperson concluded.
National Beverage plans to announce results for its second quarter ended October 30, 2021 on or before December 9, 2021.
“Patriotism” – If Only We Could Bottle It!
xair announces delay in expected launch, no longer believes they can meet Dec 31 goal. it's hard to tell by the press release if it's just FDA being slow and approval is expected any minute, or if the FDA has concerns and there is a real delay. would be a buying opportunity if it's just the first one. Down 22% pre market, and it had already come down a lot the past week.
https://www.beyondair.net/news-and-...air-provides-regulatory-update-for-lungfit-ph
https://www.beyondair.net/news-and-...air-provides-regulatory-update-for-lungfit-ph
Big High School Basketball game tonight. Two undefeated teams. Got to calm down. I've been jacked for hours already.
Last game my boy made me so proud. He had 15 rebounds.
AVTR, Unconventional was that you that recently bought this?
Avantor price target raised to $50 from $48 at Cowen 08:40 AVTR-
NOYCE!
Beyond Air no longer expects U.S. commercial launch of Lungfit PH before Dec. 31 08:41 XAIR
YIKES!
OSI Systems awarded $29M security contract 08:39 OSIS OSI Systems announced that its security division was awarded a contract valued at approximately $29M by an international customer to provide cargo and vehicle inspection systems, baggage and parcel inspection systems, related training and maintenance services.
POSSIBLE GUMMY-! EVFM
Evofem expects Q4 monthly Phexxi prescriptions to surpass 30,000 08:09 EVFM
ManTech wins $136M U.S. Marine Corps warfighting laboratory contract 08:05 MANT ManTech announced that it has been awarded a $136 million contract to support science and technology research and development for the United States Marine Corps. ManTech was awarded this contract under the Department of Defense Information Analysis Center's Multiple Award Contract. DoD IAC MAC task orders are competitively awarded by the U.S. Air Force Installation Contracting Center for work at various U.S. military organizations. The contract directly supports the Marine Corps Warfighting Laboratory in its work to identify and develop emerging and new capabilities that support Force Design 2030. The contract is for five years. ManTech is Bringing Digital to the Mission with research, development, testing and evaluation support that applies its expertise in analytics, automation, AI, Cognitive Cyber and Space Operations.
JPMorgan names top alternative energy picks for 2022 07:50 ARRY, NOVA, RUN JPMorgan analyst Mark Strouse named Array Technologies (ARRY), Sunnova Energy (NOVA) and Sunrun (SUN) his top picks for 2022 in the alternative energy and services sector. The analyst says that while investors he speaks with seem fairly skeptical that the "Build Back Better Act" will pass in its current form, the stocks he covers are trading at a discount to the average multiple immediately prior to the 2020 U.S. election. So even the passage of a shrunken down version of the bill would likely be viewed favorably, Strouse tells investors in a research note. In addition, he believes upstream input pricing should decline, particularly polysilicon, once new manufacturing capacity ramps during mid-2022. This should aid profitability along the value chain, says Strouse. Meanwhile, surging global energy prices could make renewables "even more attractive on an economic merit basis, particularly for projects that include storage," says the analyst.
Lovesac sees Q4 revenue growth of about 35% 07:47 LOVE Guidance implies $175.1M, consensus $165.4M. In its Q3 earnings call yesterday, the company stated: "For our fourth quarter, we expect sales growth of approximately 35%, with adjusted EBITDA dollars in the $12M to $13M range, compared to positive adjusted EBITDA of $25.9 million in the same quarter last year. Adjusted EBITDA is being impacted by expected lower gross margins of approximately 1,000 basis points year over year due to significant supply chain headwinds, most notably current inbound freight rate inflation versus the prior year. As we look to fiscal 2023, we remain confident in the trajectory of the business. While we are not providing formal guidance for fiscal 2023 at this time, at a high level, we expect healthy net sales growth in the high 20% range and adjusted EBITDA growth to exceed net sales growth. This is despite an expectation that supply chain headwinds persist throughout fiscal 2023. As a result of our continued supply chain headwind mitigation efforts, full year gross margins are expected to be around 50%."
Lovesac price target raised to $111 from $100 at DA Davidson 07:39 LOVE DA Davidson analyst Tom Forte raised the firm's price target on Lovesac to $111 from $100 and keeps a Buy rating on the shares. The company's Q3 earnings beat and outlook for Q4 suggest that, "at minimum", it is doing a better job of managing a challenging supply chain - particularly the tremendous inbound freight inflation - the analyst tells investors in a research note. Forte adds that Lovesac remains "small and agile enough" to outperform its peers in the home category and that he was pleased by the initial customer response to its new product offering.
Bicycle Therapeutics initiated with a Buy at Needham 07:24 BCYC
uniQure, CSL Behring announce primary endpoint reached in HOPE-B trial 07:16 QURE
Verra Mobility selloff on secondary a buying opportunity, says William Blair 07:14 VRRM
Stifel upgrades JFrog to Buy citing unique position in DevSecOps workflow » 06:35 FROG
Draganfly's Varigard spray selected by University of Alabama at Birmingham 07:47 DPRO Draganfly is pleased t
WHAT! A SPRAY... RECENTLY A TRUCK !!what is going on here!!!!!!
Last game my boy made me so proud. He had 15 rebounds.
AVTR, Unconventional was that you that recently bought this?
Avantor price target raised to $50 from $48 at Cowen 08:40 AVTR-
NOYCE!
Beyond Air no longer expects U.S. commercial launch of Lungfit PH before Dec. 31 08:41 XAIR
YIKES!
OSI Systems awarded $29M security contract 08:39 OSIS OSI Systems announced that its security division was awarded a contract valued at approximately $29M by an international customer to provide cargo and vehicle inspection systems, baggage and parcel inspection systems, related training and maintenance services.
POSSIBLE GUMMY-! EVFM
Evofem expects Q4 monthly Phexxi prescriptions to surpass 30,000 08:09 EVFM
ManTech wins $136M U.S. Marine Corps warfighting laboratory contract 08:05 MANT ManTech announced that it has been awarded a $136 million contract to support science and technology research and development for the United States Marine Corps. ManTech was awarded this contract under the Department of Defense Information Analysis Center's Multiple Award Contract. DoD IAC MAC task orders are competitively awarded by the U.S. Air Force Installation Contracting Center for work at various U.S. military organizations. The contract directly supports the Marine Corps Warfighting Laboratory in its work to identify and develop emerging and new capabilities that support Force Design 2030. The contract is for five years. ManTech is Bringing Digital to the Mission with research, development, testing and evaluation support that applies its expertise in analytics, automation, AI, Cognitive Cyber and Space Operations.
JPMorgan names top alternative energy picks for 2022 07:50 ARRY, NOVA, RUN JPMorgan analyst Mark Strouse named Array Technologies (ARRY), Sunnova Energy (NOVA) and Sunrun (SUN) his top picks for 2022 in the alternative energy and services sector. The analyst says that while investors he speaks with seem fairly skeptical that the "Build Back Better Act" will pass in its current form, the stocks he covers are trading at a discount to the average multiple immediately prior to the 2020 U.S. election. So even the passage of a shrunken down version of the bill would likely be viewed favorably, Strouse tells investors in a research note. In addition, he believes upstream input pricing should decline, particularly polysilicon, once new manufacturing capacity ramps during mid-2022. This should aid profitability along the value chain, says Strouse. Meanwhile, surging global energy prices could make renewables "even more attractive on an economic merit basis, particularly for projects that include storage," says the analyst.
Lovesac sees Q4 revenue growth of about 35% 07:47 LOVE Guidance implies $175.1M, consensus $165.4M. In its Q3 earnings call yesterday, the company stated: "For our fourth quarter, we expect sales growth of approximately 35%, with adjusted EBITDA dollars in the $12M to $13M range, compared to positive adjusted EBITDA of $25.9 million in the same quarter last year. Adjusted EBITDA is being impacted by expected lower gross margins of approximately 1,000 basis points year over year due to significant supply chain headwinds, most notably current inbound freight rate inflation versus the prior year. As we look to fiscal 2023, we remain confident in the trajectory of the business. While we are not providing formal guidance for fiscal 2023 at this time, at a high level, we expect healthy net sales growth in the high 20% range and adjusted EBITDA growth to exceed net sales growth. This is despite an expectation that supply chain headwinds persist throughout fiscal 2023. As a result of our continued supply chain headwind mitigation efforts, full year gross margins are expected to be around 50%."
Lovesac price target raised to $111 from $100 at DA Davidson 07:39 LOVE DA Davidson analyst Tom Forte raised the firm's price target on Lovesac to $111 from $100 and keeps a Buy rating on the shares. The company's Q3 earnings beat and outlook for Q4 suggest that, "at minimum", it is doing a better job of managing a challenging supply chain - particularly the tremendous inbound freight inflation - the analyst tells investors in a research note. Forte adds that Lovesac remains "small and agile enough" to outperform its peers in the home category and that he was pleased by the initial customer response to its new product offering.
Bicycle Therapeutics initiated with a Buy at Needham 07:24 BCYC
uniQure, CSL Behring announce primary endpoint reached in HOPE-B trial 07:16 QURE
Verra Mobility selloff on secondary a buying opportunity, says William Blair 07:14 VRRM
Stifel upgrades JFrog to Buy citing unique position in DevSecOps workflow » 06:35 FROG
Draganfly's Varigard spray selected by University of Alabama at Birmingham 07:47 DPRO Draganfly is pleased t
WHAT! A SPRAY... RECENTLY A TRUCK !!what is going on here!!!!!!
Evofem Biosciences, Inc. (EVFM)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.4250+0.0150(+3.66%)
At close: December 8 04:00PM EST
0.4526+0.03(+6.49%)
Pre-Market:09:17AM EST
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.4250+0.0150(+3.66%)
At close: December 8 04:00PM EST
0.4526+0.03(+6.49%)
Pre-Market:09:17AM EST
La Croix anybody tasted it.? I think the kids are drinking this Klaw thing...
- Evofem Biosciences(NASDAQ:EVFM) trades 7.8% higher premarket after it announcedbullish expectations for prescription and net revenue growth in Q4.
- Total monthly prescriptions (TRx) of Phexxi are on track to exceed 30K in Q4 representing ~70% growth from Q3 levels.
- The company expects that 57K+ women will have made the Phexxi choice from launch through year-end 2021, with almost 24K in Q4.
- "Gross revenues are on track to increase more than 50% from Q3. Shareholders should expect to see continued improvement in gross-to-net. Based on the increasing demand for Phexxi, we expect to meet or exceed the current analyst consensus estimate of net revenue in Q4," CEO Saundra Pelletier commented.
- J.P. Morgan starts off coverage on EVgo(NASDAQ:EVGO)with an Overweight rating.
- Analyst Bill Peterson and team anticipate EVGO driving outsized revenue growth on rapidly increasing fleet adoption and higher utilization.
- "We see a compelling use case for fast charging, especially in the retail and fleet segments where the company has strong and growing partnerships, and we expect the company to benefit from the rapid growth of the overall EV market over the mid- and long-term; this growth could further accelerate if the Build Back Better reconciliation bill passes in the US."
- Margin upside from software initiatives and through better negotiated energy rates over time are also anticipated.
- The firm assigns a December 2022 price target of $20.
- Shares of EVGO areup 12.16%premarket to $13.65 after jumping 4.73%